Treprostinil

曲前列尼尔

Report date: 2026/04/03 20:03:44
NME

Base Information

Drug NameTreprostinil
Drug Alias NameTreprostinilum曲前列环素Treprostinilo曲罗尼尔曲前列素 +[13] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionProstanoid IP receptor agonists
TargetsProstanoid IP receptor
Therapy Area/IndicationsHypoxiaIschemiaDelayed Graft Function +[24] 
Global Approved IndicationsPulmonary Arterial HypertensionHypertension, Pulmonary
Approved Indications in ChinaPulmonary Arterial Hypertension
Original Approved Country/TerritoryUnited States
Original Approved Date2002/05/21
Country/TerritoryCzechiaBelgiumCanada +[34] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesUnited Therapeutics Corp
China Registration ClassN/A

Develop Information

Active CompaniesShanghai Fosun Pharmaceutical (Group) Co LtdScipharm SàrlThe Brigham and Women's Hospital +[12] 
Inactive CompaniesShanghai Jiao Tong University School of MedicineCatalent Pharma SolutionsStanford University +[10] 
Active IndicationsHypoxiaDelayed Graft FunctionSarcoidosis +[12] 
Inactive IndicationsIschemiaCalcinosisFoot Ulcer +[12] 

Other Information

ATC CodeB01AC21
Related LinksWikipediaDrugBankKEGG